IsoPlexis provides the missing insights into the in vivo biology required to advance medicines & diagnostics.

Our Single-Cell Functional Proteomics technology reveals the rare subsets of highly-polyfunctional cells that simultaneously secrete multiple cytokines.

These supercells are predictive of patient response and disease progression in vivo and are responsible for orchestrating immune responses and accelerating the development of advanced, curative medicine

SUPERHUMAN BIOLOGY

Single-cell Functional Proteomics Revealing Superhero Cells in the Proteomics Landscape

Traditional technologies like bulk ELISA, Genomics, and Flow Cytometry can estimate cellular function at the population level, but these estimates do not reflect differences in that population's function.

We developed the only technology able to phenotype each immune cell by its extracellular function, revealing the unique power of the individual supercell.

IsoPlexis Unique Biology IsoPlexis Unique Biology IsoPlexis Unique Biology

Traditional multiplexed bulk assays, flow cytometry, and genomics miss critical functional immune cell attributes, thus hiding the true identity of each cell.

Only IsoPlexis captures the highly multiplexed cytokine signatures from each cell, revealing the unique power of the individual supercell.

IsoPlexis' functional difference reveals the highly proteomically multi-functional superhero immune cells that orchestrate immune response. The presence of these cells is a key predictor of early and persistent response to cancer, efficacy of vaccines, and overall survival, as published in various high impact journals.

Traditional multiplexed bulk assays, flow cytometry, and genomics miss critical functional immune cell attributes, thus hiding the true identity of each cell.

Only IsoPlexis captures the highly multiplexed cytokine signatures from each cell, revealing the unique power of the individual supercell.

IsoPlexis' functional difference reveals the highly proteomically multi-functional superhero immune cells that orchestrate immune response. The presence of these cells is a key predictor of early and persistent response to cancer, efficacy of vaccines, and overall survival, as published in various high impact journals.

Explore Our Superhuman Biology
Continue scrolling to learn how leading researchers worldwide use our superhuman biology to better the course of human health or explore these related resources.
Superhuman Cell Biology Has Been Published in 100+ Publications
Chapter 01 / 06
01
Key Takeaways
Traditional technology misses the critical functional attributes that only IsoPlexis' unique superpowered biology can reveal.
IsoPlexis' functional difference uniquely reveals the highly proteomically multi-functional superhero immune cells that orchestrate immune response.
Superhero cells are key predictors of early and persistent response to cancer, efficacy of vaccines, and overall survival, as published in various high impact journals.
Overview

Unmask the Supercells in Your Research

IsoPlexis uniquely reveals superhuman cells— highly polyfunctional cells that are early actors and orchestrators in the immune response. These rare subsets of highly functional cells can be beneficial (superheroes) or detrimental (supervillains). Detecting these cells is critical for the development of more effective immune therapies and vaccines.

Supercells Unmasked

Superhero Cells

Superhero cells are rare subsets of highly polyfunctional "super cells" that orchestrate the response against tumors and correlate to potency, persistence, and survival.

Supervillain Cells

Supervillain cells are highly polyfunctional "super cells" that drive disease progression and correlate to inflammation, toxicity, and resistance.

Why Proteome is Critical
to Superhero Cells

The proteome is complex and requires direct detection. Dynamic in vivo biology is the captured by the proteome— the key to advancing medicines and diagnostics.

Unique Superhero Cells are Key
to Fighting Cancer

By uniquely highly multiplexing the cytokines, chemokines, and phosphoproteins from each cell, IsoPlexis technology is able to uniquely reveal the orchestrator supercells — the 5-10% of cells that are early actors in immune response

Explore the Superhuman Cell Library
We developed a new library of cells characterized by functional proteomics to complement the genomic-based Human Cell Atlas.
Chapter 02 / 06
02
Key Takeaways
Polyfunctional cells secrete many different cytokines simultaneously and have correlated with outcome in multiple studies.
Only IsoPlexis can detect the true functional single-cell cytokine secretions correlative to response.
Overview

Our Leap in Innovation

IsoPlexis' breakthrough single-cell functional phenotyping technology tells you exactly what each immune cell functionally produces with a range of 30+ cytokines. This leap in innovation allows researchers to phenotype each immune cell by its extracellular function.

OUR INNOVATIVE TECHNOLOGY

Why Understanding Single Cell
Function is Critical

Cytokine function dictates the response of each cell to the tumor:

  • CD4 T cells: Cytokines orchestrate the rest of the cells to attack the tumor
  • CD8 T cells & NK Cells: Cytokines deliver the payload to the tumor
  • Macrophages & T-Reg: Cytokines drive immune suppression in the tumor
Immune
Cells
Immune
Cells
Tumor

Directly Detect the Functional Cytokines
of Each Immune Cell

Each immune cell is different, thus the complete characterization of each individual cell is critical.

While transcriptome is measured via RNA seq, and surface phenotype is measured via flow cytometry, the complete cellular definition is incomplete without measuring extracellular cytokines that are doing the work in tumor immunology.

For single cells, we're filling a gap as the only technology to do something very, obviously critical — directly detecting the functional cytokines that matter.

1
1
Functional Phenotype
SC Secretome
2
Functional Phenotype
SC Signaling
A breakthrough Technological Innovation

IsoPlexis' Innovation in Cellular
Analysis: the IsoCode Chip

Our proprietary & patented “Proteomic Barcoded” IsoCode Chip, named the Scientist's number #1 innovation, works by detecting 30+ cytokines per cell, measuring the functional phenotype of each immune cell.

This breakthrough technical innovation allows for complete single-cell functional characterization — something that was not possible before.

Chapter 03 / 06
03
Key Takeaways
ELISA & Flow Cytometry can estimate a sample's cytokine secretion, but cannot detect the highly functional cell subsets that correlate to in vivo response.
RNA-Seq can estimate function as well, but only shows a 0.4 correlation from RNA to protein.
Only IsoPlexis can detect the highly-potent single-cell subsets by capturing the range of cytokines (32+) from each cell.
Overview

What's Unique & Innovative about
IsoPlexis Single-Cell Functional Phenotyping?

Unlike IsoPlexis, these traditional methods are unable to detect the functional biological drivers that can lead to biomarker breakthroughs.

The IsoPlexis Difference
IsoPlexis Difference
True cytokines from each cell
TRUE SINGLE T CELL BIOLOGY

IsoPlexis' Breakthrough Technology

Our technology addresses the core problem that immune cells, which play a major role in cancer immunology, are heterogenous.

IsoPlexis enables researchers to fine-tune their immunotherapeutic candidates and identify what differentiates immune cell potency, cell product toxicity, and functional differences between patient responders and non-responders to immunotherapies.

COMPARISON

Traditional Methods vs IsoPlexis

Bulk Serum ELISA Averaging
Bulk Averaging
Traditional Method
Bulk Serum ELISA Averaging

Data shows that the specific cytokines produced by each heterogenous immune cell matters, yet bulk averaging masks these cellular differences.

Bulk ELISA averages serum protein information from all cells. In a variety of immunotherapy trials, stratification of responders from non-responders is not possible with bulk cytokine analysis.

Single Cell Cytokine Specificity
The IsoPlexis Difference
IsoPLexis
IsoPlexis
Our single-cell functional proteomics uniquely reveal correlates that lead to biomarker breakthroughs by detecting what each immune cell secretes in a highly multiplexed manner.
  • Captures the true single-cell protein secretion with 30+ plex full range of function
  • Detects how immune cells proteomically perform amongst a heterogenous system
  • Reveals functional biological drivers that identify patient differences
Flow Cytometry & RNA
Estimates
Traditional Method
Flow Cytometry Based Systems

Flow cytometry “surface phenotypes” for many surface markers or detects a few (1-4) blocked cytokines within the cell without detecting what's truly being secreted.

Blocking cytokines within cells increases the risk of spectral overlap and reduces the ability to multiplex cytokines reliably.

RNA-Seq based methods estimate protein function, yet are not protein measurements, with citations showing 0.4 correlation from RNA to protein1.

Reference [1]: Vogel at al. Nature Reviews Genetics (2012)

True, Highly Multiplexed Cytokines Released
The IsoPlexis Difference
IsoPLexis
IsoPlexis

Our unique functional phenotyping is directly measuring the work performed by each T cell, macrophage, or NK cell.

Each IsoCode Chip is proteomically barcoded to provide a quantitative readout of 32 cytokines per cell.

This unique functional phenotyping provides correlative clinical & pre-clinical immune biomarkers for differentiating mechanistic information in the competitive clinical world of immuno-oncology.

Chapter 04 / 06
04
Key Takeaways
IsoSpeak enables researchers to make sense of complex single-cell data by automatically generating intuitive and meaningful visualizations.
Researches can save precious time by using the in-software sample annotations & project organization for immunotherapy workflows.
IsoSpeak helps you get answers faster, with detailed informatics & statistics on cellular potency and durability, all at your fingertips.
Overview

Single-Cell Cytokine
Visualizations & Insights

IsoSpeak is the first automated informatics suite for advanced, functional, single-cell mapping and visualizations which can reveal correlative insights into true, functional immune biology.

Researchers use IsoSpeak to make sense of complex single-cell data by generating meaningful visualizations with the click of a button.

IsoSpeak's push-button user interface and advanced automation allows users to visualize, target, and utilize data from direct, functional cytokine profiling of single cells.

SOFTWARE

IsoSpeak Data
Visualizations

Researchers can use IsoSpeak to automatically generate a unique set of cellular visualizations, sample annotations, and report-ready single-cell readouts.

Chapter 05 / 06
05
Key Takeaways
We've worked hand-in-hand with the pioneers in immunology to discover correlates that were previously hidden.
Our discoveries continue to be published in leading journals such as Nature, Cancer Discovery, JITC, and Blood.
The IsoLight is the new standard found throughout the most innovative labs around the world.
Overview

Publications

IsoPlexis' functional phenotyping is critical to finding what's really happening in patients — as shown in 40+ correlative cancer immunology cases. Our functional phenotypes are illustrating the large patient differences between different types of patient responses that are undetectable on other platforms.

INSIGHTS

IsoPlexis is Uniquely Revealing the Biological Drivers of Response and Progression

IsoPlexis' functional phenotyping has been published and presented by leaders in various clinical and preclinical studies.

Additionally, we've translated that insight to accelerate pre-clinical development — illustrating large differences leading to choice.

Potency CAR-T Preclinical Discovery Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice JCI Insight , 2021 IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
Persistence
Potency
CAR-T Preclinical Discovery 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells Journal for Immunotherapy of Cancer, 2021 IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
Response
Survival
T-Cells Clinical Biomarker Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy Blood Advances, 2021 IsoCode Single-Cell Adaptive Immune: Human PBMC
Potency TILs Manufacturing & Product QC, Clinical Biomarker Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial Nature Medicine, 2021 IsoCode Single-Cell Adaptive Immune: Human T-Cell
Potency CAR-T Manufacturing & Product QC, Clinical Biomarker CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial Nature Medicine, 2021 IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
Efficacy NK Cells Preclinical Discovery Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation Communications Biology, 2021 IsoCode Single-Cell Adaptive Immune: Human NK Cell
Fitness
Response
T-Cells Preclinical Discovery, Clinical Biomarker Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production Blood, 2021 IsoCode Single-Cell Adaptive Immune: Human PBMC
Response
Survival
T-Cells Clinical Biomarker Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma Journal of Clinical Oncology, 2021 IsoCode Single-Cell Adaptive Immune: Human PBMC
Potency NK Cells Preclinical Discovery Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors Cytotherapy, 2021 IsoCode Single-Cell Adaptive Immune: Human NK Cell
Potency NK Cells Preclinical Discovery NF-κB c-Rel Is Dispensable for the Development but Is Required for the Cytotoxic Function of NK Cells Frontiers in Immunology, 2021 IsoCode Single-Cell Adaptive Immune: Human NK Cell
Potency CAR-T Preclinical Discovery Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity Molecular Therapy, 2021 IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
Potency T-Cells Preclinical Discovery, Clinical Biomarker Use of Multi-Site Radiation Therapy for Systemic Disease Control International Journal of Radiation Oncology, Biology, Physics, 2021 IsoCode Single-Cell Adaptive Immune: Human PBMC
Response T-Cells Clinical Biomarker Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancer Clinical Cancer Research, 2020 IsoCode Single-Cell Adaptive Immune: Human PBMC
Potency T-Cells Preclinical Discovery Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141+ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8+ T Cell Response in Human Immune System Mice Frontiers in Immunology, 2020 IsoCode Single-Cell Adaptive Immune: Human PBMC
Persistence
Potency
NK Cells Preclinical Discovery Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes in vivo Persistence and Enhances Anti-tumor Activity Cell Stem Cell, 2020 IsoCode Single-Cell Adaptive Immune: Human NK Cell
Potency CAR-T Preclinical Discovery CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression Leukemia, 2020 IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
Persistence
Potency
CAR-T Preclinical Discovery Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice Gastroenterology, 2020 IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
Persistence
Potency
T-Cells, NK Cells Preclinical Discovery, Clinical Biomarker Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist Nature Communications, 2020 IsoCode Single-Cell Adaptive Immune: Human PBMC
Potency CAR-T Preclinical Discovery Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma Blood Advances, 2019 IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
Response CAR-T Clinical Biomarker, Manufacturing & Product QC Preinfusion Polyfunctional Anti-CD19 Chimeric Antigen Receptor T Cells Associate with Clinical Outcomes in NHL Blood, 2018 IsoCode Single-Cell Adaptive Immune: Human CAR-T Using AF647-Conjugated Antibodies to CD4 and CD8
Potency T-Cells Preclinical Discovery, Clinical Biomarker A Kinetic Investigation of Interacting, Stimulated T Cells Identifies Conditions for Rapid Functional Enhancement, Minimal Phenotype Differentiation, and Improved Adoptive Cell Transfer Tumor Eradication PLOS One, 2018 IsoCode Single-Cell Adaptive Immune: Human PBMC with PMA & Ionomycin
Cancer
Immunology
Single Cell Solution Cell Type Predictive in Indication & Related Statistics
SC-PFS (H)
T cell (H)
Peg-IL2 in Melanoma pre-clinically.2
SC-PFS (H)
T cell (H)
Melanoma response (ipi/nivo)
P = 0.029
SC-PFS (H)
T cell (H)
AML response in checkpoint.
P = 0.0288
SC-PFS (H)
T cell (H)
Pancreatic cancer survival
P = 0.001
SC-PFS (H)
T cell (H)
Pre-clinical NP cancer vaccine efficacy
P = 0.003
SC-IM (M)
Monocyte (H)
Monocyte Tumor suppression correlates
Cell Therapies
Single Cell Solution Cell Type Predictive in Indication & Related Statistics
SC-PFS (H)
CAR-T (H)
Trimeric CAR in BCMA / Myeloma
SC-PFS (H)
CAR-T (H)
Pre-infusion CAR-T in DLBCL.
P = 0.012
SC-PFS (M)
NK cell (M)
Pre-clinical correlates with in vivo mouse studies in TCR & NK cell Therapy
Immune Inflammation
Single Cell Solution Cell Type Predictive in Indication & Related Statistics
SC-PFI (H)
Monocyte (H)
MS progression.
P = 0.035
SC-PFI (H)
CD34+ (H)
PV vs. ET (myelofibrosis).
P = 0.018
SC-PFI (H)
T cell (H)
Neuroinflammation
PUBLICATIONS

Published in 100+ High-Impact Journals

Our superhuman biology helps researchers around the world change the course of advanced medicines and complex diseases.

Press Type
2022
Press Type

VACCINES & INFECTIOUS DISEASE

Li L et al., "In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals", JCI Insight, 2022

Press Type

CELLULAR AND REGENERATIVE MEDICINE

Fernandez-Yague MA et al., "Analyzing immune response to engineered hydrogels by hierarchical clustering of inflammatory cell subsets", Science Advances, 2022

Press Type

Cancer Immunology

Friedman et al., "Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses", Journal for ImmunoTherapy of Cancer, 2022

Press Type

VACCINES & INFECTIOUS DISEASE

Su Yet al., "Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae", Cell, 2022

Press Type
2021
Press Type

CELLULAR AND REGENERATIVE MEDICINE

Thomas A et al., "Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice", JCI Insight, 2021

Press Type

CELLULAR AND REGENERATIVE MEDICINE

Roselli E et al., "4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells", Journal for ImmunoTherapy of Cancer, 2021

Press Type

Cancer Immunology

Abbas H et al., "Single-cell Polyfunctional Proteomics of CD4 Cells from Patients with AML Predicts Responses to Anti-PD-1-based therapy", Blood Advances, 2021

Press Type

CELLULAR AND REGENERATIVE MEDICINE

Gionet-Gonzales M et al., "Sulfated Alginate Hydrogels Prolong the Therapeutic Potential of MSC Spheroids by Sequestering the Secretome", Advanced Healthcare Materials, 2021

Press Type

Cancer Immunology

Creelan BC et al., "Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial", Nature Medicine, 2021

Press Type

Cellular and Regenerative Medicine

Spiegel JY et al., "CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase I trial", Nature Medicine, 2021

Press Type

Cancer Immunology

Dhar P et al., "Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation", Communications Biology, 2021

Press Type

Cancer Immunology

Dhar P et al., "Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation", Communications Biology, 2021

Press Type

Cancer Immunology

Boklee J et al., "Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production", Blood, 2021

Press Type

Cancer Immunology

Diab A et al., "Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma", Journal of Clinical Oncology, 2021

Press Type

Cellular and Regenerative Medicine

Chockley P et al., "Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors", Cytotherapy, 2021

Press Type

Cancer Immunology

Mahmoud A et al., "Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression", iScience, 2021

Press Type

Cancer Immunology, Cellular and Regenerative Medicine

Ruiz F et al., "Comprehensive Activation Profiling of Tabelecleucel, an Off-The-Shelf, Allogeneic EBV-Specific T-Cell Immunotherapy", Hematological Oncology, 2021

Press Type

Cancer Immunology

Vicioso Y et al., "NF-κB c-Rel Is Dispensable for the Development but Is Required for the Cytotoxic Function of NK Cells", Frontiers in Immunology, 2021

Press Type

Vaccines & Infectious Disease

Szabo PA et al., "Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19", Immunity, 2021

Press Type

Cellular and Regenerative Medicine

McKenna MK et al., "Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity", Molecular Therapy, 2021

Press Type

Oncology

Patel RR et al., "Use of Multi-Site Radiation Therapy for Systemic Disease Control", International Journal of Radiation Oncology*Biology*Physics. 2021., 2021

Press Type

Cellular and Regenerative Medicine

Xie CB et al., "Complement‐activated human endothelial cells stimulate increased polyfunctionality in alloreactive T cells", American Journal of Transplantation, 2021

Our Biology

The New Standard in
Single-Cell Biology

We help researchers around the world accelerate the next generation of cancer immunotherapy with functional immunology.

"Quality assays are mainly descriptive with some objective parameters like cytokine production, cytotoxicity, and proliferation. Only recently, with PSI… can we start to differentiate products."
Marco L Davila
Moffitt Cancer Center
"As a cancer research center with a key focus on CAR-T and other cell therapies, we feel that IsoPlexis will enable us to better characterize response and potentially predict whether cancer patients will respond to CAR-T therapy before treatment."
Christine Brown
City of Hope
"Current assays that rely on single-plex ELISA or even multiparametric flow cytometry don't give you the level of resolution that the IsoPlexis platform can provide."
John Rossi
Kite Pharma
Chapter 06 / 06
06

The Superhuman Cell Company

Join researchers worldwide using IsoPlexis to reclaim lab time, save precious samples, increase efficacy, and cut down therapeutic timelines by a year+.